Post by Myriad Genetics

Did you know that 8 in 10 of your low and favorable intermediate-risk patients could potentially avoid treatment?¹ ² The Prolaris® Prostate Cancer Prognostic Test outperforms all other biomarkers in selecting active surveillance candidates and identifies twice as many men in low-risk groups than brand competitors.¹ This test stratifies risk through cell-cycle progression gene expression, which has proven most prognostic for understanding individual prostate cancer aggressiveness and disease mortality.³ Get started with the Prolaris Test: https://brnw.ch/21x2F85 #ProstateCancer #GeneticInsights #CancerCare #ActiveSurveillance https://brnw.ch/21x2F84 JC, Tosoian JJ, Qi J, et al. Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. JCO Precis Oncol. 2018;2:PO.18.00163. 2.Lenz L, Clegg W, Iliev D, et al. Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing. Prostate Cancer Prostatic Dis. 2025;28(2):427-434. 3.Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106(6):1095-1099.